Greater Trust and Demand for Antibody Tests Key to Reopening Economy May 12, 2020 - Baystreet.ca Health officials say antibody tests are key to reopening the U.S. economy. However, according to Harvard researchers, as noted by CBS News, for that to happen successfully, “the U.S. needs to triple the current rate of testing to at least 500,000 people per day.” To assist, and help create better testing, the US FDA just released new guidelines to increase oversight. In fact, under the new rules, according to the U.S. FDA, as noted by The Washington Post, “companies already marketing tests will be required to file applications for FDA emergency-use authorizations, including data on their tests, within 10 business days. Makers of new tests will have to file such applications within 10 days of notifying the agency of their plans to go to market. Under such authorizations, the FDA allows unapproved medical products to be used in a public health emergency without being subjected to a full-fledged review.” Greater trust, and demand for antibody testing only likely to gain momentum is creating opportunity for companies such as Blackhawk Growth Corp. (CSE:BLR)(OTC:BLRZF), Laboratory Corp. of America Holdings (NYSE:LH), Abbott Laboratories (NYSE:ABT), Quest Diagnostics Inc. (NYSE:DGX), and Roche Holdings (OTC:RHHBY). Blackhawk Growth Corp. (CSE:BLR)(OTC:BLRZF) BREAKING NEWS: Blackhawk Growth Corp. just announced that in response to more politicians demanding increased testing and recent comments from Governor Andrew Cuomo of New York stating, “The more testing, the more open the economy”, Blackhawk Growth Corp. announced that it has signed a non-exclusive distribution agreement with a private arms-length California-based entity to distribute Innovita’s 2019-nCoV Ab testing kits used in the detection of antibodies associated with COVID-19. The distributor will be responsible for their own costs associated with the distribution of the test kits to healthcare clinics, government organizations, pharmacies and retailers in the US, and all profits will be divided evenly between Blackhawk and the distributor. “As United States President Donald Trump looks to reopen the economy, it will be imperative that everyone going back to work gets tested” said Frederick Pels, CEO of Blackhawk. “The goal of this distribution agreement is to give Blackhawk an American influence and point of contact, further proving to the country that we’re able to deliver these kits in record time. The more exposure we’re able to get with various healthcare clinics, large corporations, nursing homes and everywhere else where employee testing is prevalent, should bode well for our test kits and our shareholders. These kits need to be in the hands of more organizations and this agreement adds yet another voice in the fight against COVID-19.” “Delivering these kits and putting them in the hands of citizens and various levels of government is the exact market we’re targeting” continued Mr. Pels. “Having a distributor out there allows us to open new avenues and increases the exposure we need to land and close much larger orders.” Other related developments from around the markets include: Laboratory Corp. of America Holdings (NYSE:LH) announced that its COVID-19 Immunoglobulin G (IgG) antibody test is now available for individuals through LabCorp.com. With the addition of this latest offering, individuals have the ability to receive the COVID-19 IgG antibody test from their doctor, in person or through a telemedicine program, and now directly using LabCorp.com. LabCorp does not require upfront out-of-pocket costs for the IgG antibody test. If the individual uses LabCorp.com to get the test, there is a non-reimbursable fee of $10 paid to PWNHealth to cover the independent physician service costs. If the test is ordered through the individual’s doctor or healthcare provider, the $10 PWNHealth fee does not apply. “We are working as quickly as possible to develop and implement new solutions to combat COVID-19,” said Adam Schechter, president and CEO of LabCorp. “We continue to bring our deep research and scientific expertise to the market, and are now making it more convenient for people to access our tests through our wide network of physicians, hospitals and healthcare providers, and now through LabCorp.com.” Abbott Laboratories (NYSE:ABT) announced that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the company's SARS-CoV-2 IgG lab-based serology blood test on the Alinity™ i system. Abbott plans to ship nearly 30 million antibody tests globally in May across its ARCHITECT® and Alinity i™ platforms and will have capacity for 60 million tests in June. Antibody testing will help provide a greater understanding of the virus, including how long antibodies stay in the body and how much of the population has been infected. Last month, Abbott received FDA EUA and CE Mark for its SARS-CoV-2 IgG antibody blood test on the ARCHITECT system.* Abbott has already begun shipping antibody tests for use on the ARCHITECT systems globally including in the U.S., UK, Italy, Spain and India. Having more options of highly reliable tests across our platforms will help healthcare workers and health officials as they conduct broad scale testing for COVID-19," said Robert B. Ford, president and chief executive officer, Abbott. "Abbott is a leader in providing antibody testing at large scale on multiple systems, which is helping meet the needs of laboratories as they look to build testing capacity." Quest Diagnostics Inc. (NYSE:DGX) performs and reports results of 1.7 million COVID-19 diagnostic tests and 620,000 antibody tests to date. Plans to double molecular diagnostic testing capacity to 100,000 tests a day in June amid expectations of growing demand. Expands antibody test capacity with addition of Ortho Clinical Diagnostics IgG Antibody Test. Quest has performed and reported results of approximately 1.7 million COVID-19 diagnostic tests since we introduced these services on March 9. These tests use molecular technologies to detect the RNA of the virus that causes COVID-19, aiding diagnosis. We have capacity to perform more than 50,000 diagnostic COVID-19 tests per day or approximately 350,000 tests per week. We are reporting our diagnostic test results in 1-2 days on average. Roche Holdings (OTC:RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA)1 for its new Elecsys® Anti-SARS-CoV-2 antibody test. The test is designed to help determine if a patient has been exposed to the SARS-CoV-2 virus and if the patient has developed antibodies against SARS-CoV-2. Roche has already started shipping the new antibody test to leading laboratories globally and will ramp up production capacity to high double-digit millions per month to serve healthcare systems in countries accepting the CE mark2 as well as the U.S. “Thanks to the enormous efforts of our dedicated colleagues we are now able to deliver a high-quality antibody test in high quantities, so we can support healthcare systems around the world with an important tool to better manage the COVID-19 health crisis,” said Severin Schwan, CEO Roche Group. ”I am in particular pleased about the high specificity and sensitivity of our test, which is crucial to support health care systems around the world with a reliable tool to better manage the COVID-19 health crisis.” Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Blackhawk Growth Corp. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Blackhawk Growth Corp. Please click here for full disclaimer. Contact Information: 2818047972 ty@wallstreetnation.com
Greater Trust and Demand for Antibody Tests Key to Reopening Economy May 12, 2020 - Baystreet.ca Health officials say antibody tests are key to reopening the U.S. economy. However, according to Harvard researchers, as noted by CBS News, for that to happen successfully, “the U.S. needs to triple the current rate of testing to at least 500,000 people per day.” To assist, and help create better testing, the US FDA just released new guidelines to increase oversight. In fact, under the new rules, according to the U.S. FDA, as noted by The Washington Post, “companies already marketing tests will be required to file applications for FDA emergency-use authorizations, including data on their tests, within 10 business days. Makers of new tests will have to file such applications within 10 days of notifying the agency of their plans to go to market. Under such authorizations, the FDA allows unapproved medical products to be used in a public health emergency without being subjected to a full-fledged review.” Greater trust, and demand for antibody testing only likely to gain momentum is creating opportunity for companies such as Blackhawk Growth Corp. (CSE:BLR)(OTC:BLRZF), Laboratory Corp. of America Holdings (NYSE:LH), Abbott Laboratories (NYSE:ABT), Quest Diagnostics Inc. (NYSE:DGX), and Roche Holdings (OTC:RHHBY). Blackhawk Growth Corp. (CSE:BLR)(OTC:BLRZF) BREAKING NEWS: Blackhawk Growth Corp. just announced that in response to more politicians demanding increased testing and recent comments from Governor Andrew Cuomo of New York stating, “The more testing, the more open the economy”, Blackhawk Growth Corp. announced that it has signed a non-exclusive distribution agreement with a private arms-length California-based entity to distribute Innovita’s 2019-nCoV Ab testing kits used in the detection of antibodies associated with COVID-19. The distributor will be responsible for their own costs associated with the distribution of the test kits to healthcare clinics, government organizations, pharmacies and retailers in the US, and all profits will be divided evenly between Blackhawk and the distributor. “As United States President Donald Trump looks to reopen the economy, it will be imperative that everyone going back to work gets tested” said Frederick Pels, CEO of Blackhawk. “The goal of this distribution agreement is to give Blackhawk an American influence and point of contact, further proving to the country that we’re able to deliver these kits in record time. The more exposure we’re able to get with various healthcare clinics, large corporations, nursing homes and everywhere else where employee testing is prevalent, should bode well for our test kits and our shareholders. These kits need to be in the hands of more organizations and this agreement adds yet another voice in the fight against COVID-19.” “Delivering these kits and putting them in the hands of citizens and various levels of government is the exact market we’re targeting” continued Mr. Pels. “Having a distributor out there allows us to open new avenues and increases the exposure we need to land and close much larger orders.” Other related developments from around the markets include: Laboratory Corp. of America Holdings (NYSE:LH) announced that its COVID-19 Immunoglobulin G (IgG) antibody test is now available for individuals through LabCorp.com. With the addition of this latest offering, individuals have the ability to receive the COVID-19 IgG antibody test from their doctor, in person or through a telemedicine program, and now directly using LabCorp.com. LabCorp does not require upfront out-of-pocket costs for the IgG antibody test. If the individual uses LabCorp.com to get the test, there is a non-reimbursable fee of $10 paid to PWNHealth to cover the independent physician service costs. If the test is ordered through the individual’s doctor or healthcare provider, the $10 PWNHealth fee does not apply. “We are working as quickly as possible to develop and implement new solutions to combat COVID-19,” said Adam Schechter, president and CEO of LabCorp. “We continue to bring our deep research and scientific expertise to the market, and are now making it more convenient for people to access our tests through our wide network of physicians, hospitals and healthcare providers, and now through LabCorp.com.” Abbott Laboratories (NYSE:ABT) announced that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the company's SARS-CoV-2 IgG lab-based serology blood test on the Alinity™ i system. Abbott plans to ship nearly 30 million antibody tests globally in May across its ARCHITECT® and Alinity i™ platforms and will have capacity for 60 million tests in June. Antibody testing will help provide a greater understanding of the virus, including how long antibodies stay in the body and how much of the population has been infected. Last month, Abbott received FDA EUA and CE Mark for its SARS-CoV-2 IgG antibody blood test on the ARCHITECT system.* Abbott has already begun shipping antibody tests for use on the ARCHITECT systems globally including in the U.S., UK, Italy, Spain and India. Having more options of highly reliable tests across our platforms will help healthcare workers and health officials as they conduct broad scale testing for COVID-19," said Robert B. Ford, president and chief executive officer, Abbott. "Abbott is a leader in providing antibody testing at large scale on multiple systems, which is helping meet the needs of laboratories as they look to build testing capacity." Quest Diagnostics Inc. (NYSE:DGX) performs and reports results of 1.7 million COVID-19 diagnostic tests and 620,000 antibody tests to date. Plans to double molecular diagnostic testing capacity to 100,000 tests a day in June amid expectations of growing demand. Expands antibody test capacity with addition of Ortho Clinical Diagnostics IgG Antibody Test. Quest has performed and reported results of approximately 1.7 million COVID-19 diagnostic tests since we introduced these services on March 9. These tests use molecular technologies to detect the RNA of the virus that causes COVID-19, aiding diagnosis. We have capacity to perform more than 50,000 diagnostic COVID-19 tests per day or approximately 350,000 tests per week. We are reporting our diagnostic test results in 1-2 days on average. Roche Holdings (OTC:RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA)1 for its new Elecsys® Anti-SARS-CoV-2 antibody test. The test is designed to help determine if a patient has been exposed to the SARS-CoV-2 virus and if the patient has developed antibodies against SARS-CoV-2. Roche has already started shipping the new antibody test to leading laboratories globally and will ramp up production capacity to high double-digit millions per month to serve healthcare systems in countries accepting the CE mark2 as well as the U.S. “Thanks to the enormous efforts of our dedicated colleagues we are now able to deliver a high-quality antibody test in high quantities, so we can support healthcare systems around the world with an important tool to better manage the COVID-19 health crisis,” said Severin Schwan, CEO Roche Group. ”I am in particular pleased about the high specificity and sensitivity of our test, which is crucial to support health care systems around the world with a reliable tool to better manage the COVID-19 health crisis.” Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Blackhawk Growth Corp. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Blackhawk Growth Corp. Please click here for full disclaimer. Contact Information: 2818047972 ty@wallstreetnation.com